Strategic collaboration focused on the supply of clinical trial materials for IND’s filed in China and the US.
China-based Adagene, Inc. was founded with the goal of becoming a leading player in antibody discovery and engineering. Its proprietary dynamic precision library (DPL) has enabled the company to establish a pipeline of novel antibody therapeutics that are moving into clinical trials. The company has raised of $36 million through two series of financing and counts F-Prime Capital (formerly Fidelity Biosciences), Eight Roads Ventures China (formerly Fidelity Growth Partners Asia), 6 Dimensions Capital, GP Healthcare Capital and New World TMT as investors.
Reflecting the success of its pipeline candidates, Adagene recently announced a strategic collaboration with WuXi Biologics for the production of clinical trial materials to support Investigational New Drug (IND) applications in both China and the U.S. Adagene specializes in antibody drugs that target difficult antigens and that have enhanced biophysical properties.
WuXi Biologics offers end-to-end solutions designed to help customers discover, develop and manufacture biologic drugs. The company is committed to providing a one-stop service offering and value proposition.
"The strategic collaboration with WuXi Biologics will enable Adagene to focus on our core competency in the discovery of novel antibody therapeutics, and by leveraging the process development and manufacturing capabilities of WuXi Biologics will accelerate Adagene's next wave of innovative products into the clinic," said Dr. Peter Luo, co-founder and chief executive officer of Adagene.
Added Dr. Chris Chen, Chief Executive Officer of WuXi Biologics: "We are pleased to work closely with Adagene in developing and manufacturing some urgently-needed antibody therapeutics through the world-class, high-quality biologics platform at WuXi Biologics. The collaboration is expected to introduce the world-class life-saving biologics to the Chinese market, and then benefit patients around the world."
